Brightly colored prescription warning labels applied by pharmacies fail to adequately capture the attention of older patients, suggesting that current labeling standards should be reconsidered to make them more effective, according to a study published online June 14 in PLoS ONE.
Brightly colored prescription warning labels (PWLs) applied by pharmacies fail to adequately capture the attention of older patients, suggesting that current labeling standards should be reconsidered to make them more effective, according to a study published online June 14 in PLoS ONE.
According to lead researcher Raghav Prashant Sundar, a graduate student at the School of Packaging, Michigan State University, East Lansing, Mich., and colleagues, there are currently no universal federal standards for the presentation of information on PWLs and little is known about how patients access and use prescription labeling.
By tracking eye movements, Sundar and colleagues investigated the effectiveness of PWLs in conveying warning information to 2 groups of patients: 15 young adults (7 males, 8 females, age range of 20–29, with an average age of 22.8 years) and 17 adults over the age of 50 (5 males, 12 females, age range of 51–77, with an average age of 62.2 years).
The analyses showed that older patients were less likely to notice a PWL than younger patients (54.0%±17.6% and 91.8%±6.1%, respectively; P=.0396), and color did not appear to increase noticeability.
Although all patients were more likely to direct their gaze at the white pharmacy label (1.35±0.11) than the PWL (0.68±0.07) (P<.05), older patients were less likely to remember PWLs on bottles they had examined, which, the researchers suggest was more a result of where their attention went rather than memory lapse. Gaze tracking indicated that older patients made less total shifts (0.47±0.06) between areas on the bottle than the younger patients (0.85±0.09).
“These data have important implications for understanding possible shortcomings of current PWLs. They provide insight into a potential cause of age-related differences in PWL effectiveness, and suggest that designers should, at least in part, focus on attracting attention,” the authors wrote.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More